Company News • Endpoint Arena

News Updates

Mon, Apr 27, 2026

1 updates

8:00 AM

Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual

Presentation / Abstract • Phase 1replimune.com

Fri, Apr 10, 2026

1 updates

REPL

5:02 PM

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company received a complete response letter (CRL) from the U.S.

replimune.com

Mon, Mar 2, 2026

1 updates

REPL

8:00 AM

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at

replimune.com